UNIGE document Scientific Article
previous document  unige:101427  next document
add to browser collection
Title

Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials

Authors
Beyer-Westendorf, Jan
Lensing, Anthonie W A
Arya, Roopen
Cohen, Alexander T
Wells, Philip S
Middeldorp, Saskia
Verhamme, Peter
show hidden authors show all authors [1 - 15]
Published in Thrombosis Research. 2017, vol. 149, p. 29-37
Abstract The results of the EINSTEIN-DVT/PE and AMPLIFY trials, which compared rivaroxaban and apixaban with conventional anticoagulation therapy for acute venous thromboembolism (VTE), respectively, are often compared. However, the trials differed in duration of therapy (3-12 and 6months, respectively) and in patient selection (few exclusion criteria and more stringent exclusion criteria, respectively).
Keywords AdultAgedCohort StudiesFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useFemaleHemorrhage/chemically inducedHumansMaleMiddle AgedPatient SelectionPyrazoles/administration & dosage/adverse effects/therapeutic usePyridones/administration & dosage/adverse effects/therapeutic useRivaroxaban/administration & dosage/adverse effects/therapeutic useTreatment OutcomeVenous Thromboembolism/drug therapy
Identifiers
PMID: 27886530
Full text
Article (Published version) (699 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group La maladie thromboembolique veineuse (808)
Citation
(ISO format)
BEYER-WESTENDORF, Jan et al. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. In: Thrombosis Research, 2017, vol. 149, p. 29-37. https://archive-ouverte.unige.ch/unige:101427

43 hits

0 download

Update

Deposited on : 2018-01-16

Export document
Format :
Citation style :